UY33985A - Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida - Google Patents

Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida

Info

Publication number
UY33985A
UY33985A UY0001033985A UY33985A UY33985A UY 33985 A UY33985 A UY 33985A UY 0001033985 A UY0001033985 A UY 0001033985A UY 33985 A UY33985 A UY 33985A UY 33985 A UY33985 A UY 33985A
Authority
UY
Uruguay
Prior art keywords
dihydroimidazo
salts
substituted quinazoline
quinazoline
substituted
Prior art date
Application number
UY0001033985A
Other languages
English (en)
Inventor
Dr Jan-Georg Peters
Dr Hans-Christian Militzer
Dr Hartwig Mueller
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33985(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of UY33985A publication Critical patent/UY33985A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sal de diclorhidrato de 2-amino-N-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin- 5-il]pirimidin-5-carboxamida de Fórmula (II), o un tautómero, solvato o hidrato de la misma.
UY0001033985A 2011-04-05 2012-03-28 Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida UY33985A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (1)

Publication Number Publication Date
UY33985A true UY33985A (es) 2012-10-31

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033985A UY33985A (es) 2011-04-05 2012-03-28 Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida

Country Status (42)

Country Link
US (2) US10383876B2 (es)
EP (2) EP2508525A1 (es)
JP (2) JP5763834B2 (es)
KR (1) KR101937501B1 (es)
CN (1) CN103649091B (es)
AP (1) AP3709A (es)
AR (1) AR085718A1 (es)
AU (1) AU2012238891B2 (es)
BR (1) BR112013025549A2 (es)
CA (1) CA2832123C (es)
CL (1) CL2013002870A1 (es)
CO (1) CO6781534A2 (es)
CR (1) CR20130511A (es)
CU (1) CU24208B1 (es)
CY (1) CY1116231T1 (es)
DK (1) DK2694508T3 (es)
DO (1) DOP2013000223A (es)
EA (1) EA023646B1 (es)
EC (1) ECSP13013006A (es)
ES (1) ES2529653T3 (es)
GT (1) GT201300234A (es)
HK (1) HK1195907A1 (es)
HR (1) HRP20150138T1 (es)
IL (1) IL228561A (es)
JO (1) JO2958B1 (es)
MA (1) MA35014B1 (es)
ME (1) ME02021B (es)
MX (1) MX336057B (es)
MY (1) MY169452A (es)
PE (1) PE20141038A1 (es)
PL (1) PL2694508T3 (es)
PT (1) PT2694508E (es)
RS (1) RS53811B1 (es)
SG (1) SG193595A1 (es)
SI (1) SI2694508T1 (es)
SM (1) SMT201500037B (es)
TN (1) TN2013000401A1 (es)
TW (2) TWI592158B (es)
UA (1) UA111604C2 (es)
UY (1) UY33985A (es)
WO (1) WO2012136553A1 (es)
ZA (1) ZA201307105B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
MX2015014171A (es) * 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
JP2016521715A (ja) 2013-06-14 2016-07-25 バイエル ファーマ アクチエンゲゼルシャフト 抗tweakr抗体およびその使用
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
MX2017011607A (es) * 2015-03-09 2018-04-10 Bayer Pharma AG Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas.
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリンを含んでいる組合せ
WO2016150899A2 (en) 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
MA43957A (fr) 2016-02-01 2018-12-12 Bayer Pharma AG Biomarqueurs de copanlisib
JP2019512003A (ja) 2016-02-01 2019-05-09 バイエル ファーマ アクチエンゲゼルシャフト コパンリシブバイオマーカー
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
EP3426657B1 (en) 2016-03-08 2022-07-13 Bayer Pharma Aktiengesellschaft 2 amino n [7 methoxy 2, 3-dihydroimidazo-[1, 2-c]quinazolin-5-yl]pyrimidine 5 carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
JP2019532922A (ja) 2016-09-23 2019-11-14 バイエル ファーマ アクチエンゲゼルシャフト Pi3k−阻害剤の組み合わせ
AU2017376766A1 (en) 2016-12-14 2019-06-06 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
EP3585437B1 (en) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
IL272857B2 (en) 2017-09-08 2024-03-01 Bayer Consumer Care Ag Cofanalisib formulations
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
US20210187134A1 (en) 2018-08-28 2021-06-24 Bayer As Combination of pi3k-inhibitors and targeted thorium conjugates
CA3116230A1 (en) * 2018-10-16 2020-04-23 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
CN112930212A (zh) * 2018-10-17 2021-06-08 桑多斯股份公司 包含左甲状腺素和二羧酸的共晶体
US20220064171A1 (en) * 2018-12-27 2022-03-03 Holosmedic Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (es) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
SI1549652T1 (sl) * 2002-09-30 2009-04-30 Bayer Healthcare Ag Kondenzirani azolpirimidinski derivati
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP5620275B2 (ja) * 2008-01-14 2014-11-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された2,3−ジヒドロイミダゾ[1,2−c]キナゾリン誘導体類
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
MA34158B1 (fr) 2010-04-16 2013-04-03 Bayer Ip Gmbh Combinaisons contenant une 2,3-dihydroimidazo{1,2-c]quinazoline substituée
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
MX2015014171A (es) 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
EP3077002B1 (en) 2013-12-03 2020-04-22 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリンを含んでいる組合せ
MX2017011607A (es) * 2015-03-09 2018-04-10 Bayer Pharma AG Uso de 2,3-dihidroimidazol[1,2-c]quinazolinas sustituidas.

Also Published As

Publication number Publication date
JP5826961B2 (ja) 2015-12-02
TN2013000401A1 (en) 2015-03-30
HK1195907A1 (zh) 2014-11-28
MY169452A (en) 2019-04-11
SI2694508T1 (sl) 2015-03-31
AP2013007219A0 (en) 2013-10-31
IL228561A0 (en) 2013-12-31
JO2958B1 (en) 2016-03-15
EP2694508B1 (en) 2014-11-19
TWI549954B (zh) 2016-09-21
JP5763834B2 (ja) 2015-08-12
EP2694508A1 (en) 2014-02-12
US20140072529A1 (en) 2014-03-13
TW201637656A (zh) 2016-11-01
CN103649091A (zh) 2014-03-19
PT2694508E (pt) 2015-02-10
JP2014510119A (ja) 2014-04-24
UA111604C2 (uk) 2016-05-25
WO2012136553A1 (en) 2012-10-11
SMT201500037B (it) 2015-05-05
CU24208B1 (es) 2016-11-29
CN103649091B (zh) 2016-06-22
TW201249847A (en) 2012-12-16
IL228561A (en) 2015-10-29
HRP20150138T1 (hr) 2015-05-08
AU2012238891A1 (en) 2013-10-24
RS53811B1 (en) 2015-06-30
EA023646B1 (ru) 2016-06-30
KR20140021637A (ko) 2014-02-20
EP2508525A1 (en) 2012-10-10
ECSP13013006A (es) 2013-12-31
CL2013002870A1 (es) 2014-06-20
NZ616198A (en) 2015-09-25
GT201300234A (es) 2015-01-16
MA35014B1 (fr) 2014-04-03
CY1116231T1 (el) 2017-02-08
CA2832123C (en) 2018-09-11
US20160193219A1 (en) 2016-07-07
ES2529653T3 (es) 2015-02-24
SG193595A1 (en) 2013-10-30
KR101937501B1 (ko) 2019-01-10
PE20141038A1 (es) 2014-09-05
TWI592158B (zh) 2017-07-21
AP3709A (en) 2016-05-31
PL2694508T3 (pl) 2015-04-30
BR112013025549A2 (pt) 2016-12-27
CO6781534A2 (es) 2013-10-31
US9636344B2 (en) 2017-05-02
AU2012238891B2 (en) 2016-12-01
CA2832123A1 (en) 2012-10-11
ME02021B (me) 2015-05-20
DK2694508T3 (en) 2015-02-16
JP2015164936A (ja) 2015-09-17
EA201391470A1 (ru) 2014-03-31
CU20130133A7 (es) 2014-01-29
CR20130511A (es) 2013-12-04
MX336057B (es) 2016-01-07
DOP2013000223A (es) 2013-11-15
MX2013011583A (es) 2013-12-16
US10383876B2 (en) 2019-08-20
ZA201307105B (en) 2014-11-26
AR085718A1 (es) 2013-10-23

Similar Documents

Publication Publication Date Title
UY33985A (es) Sales de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY33984A (es) Uso de 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34156A (es) Compuestos inhibidores de metaloenzimas
CY1119804T1 (el) Συντηγμενες τετρα- ή πεντα-κυκλικες διϋδροδιαζεπινοκαρβαζολονες ως αναστολεις parp
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34034A (es) Triazolopiridinas
UY33970A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
UY34374A (es) Benzilindazoles sustituidos
UY4149Q (es) Golosina para mascota
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201491304A1 (ru) Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
UY33978A (es) Piridinonas bicíclicas nuevas.
UY34006A (es) Imidazopiridazinas
UY34559A (es) Inhibidores de bromodominios
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34550A (es) Bencilpirazoles sustituidos
UY34502A (es) Arilos y heteroarilos bicíclicos inhibidores de los canales de sodio
UY34318A (es) ?derivados de isotiazolina útiles como compuestos insecticidas?
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
GT201200016S (es) Diseño de golosina para mascotas
UY34523A (es) Derivados de betulina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019